Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BETd-260, a PROTAC linked by a Cereblon ligand and a BET ligand, has an inhibitory effect on BRD4 protein in leukemic cell lines.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 212.00 | |
5 mg | In stock | $ 398.00 | |
10 mg | In stock | $ 592.00 | |
25 mg | In stock | $ 947.00 | |
50 mg | In stock | Inquiry |
Description | BETd-260, a PROTAC linked by a Cereblon ligand and a BET ligand, has an inhibitory effect on BRD4 protein in leukemic cell lines. |
Targets&IC50 | BRD3:30-100 pM, BRD:0.0022 μM, BRD2:30-100 pM, BRD4:<30 pM |
In vitro | betd - 260 (ZBC260; Compound 23) induced the degradation of BRD2, BRD3 and BRD4 proteins. BETd-260 acted on RS4; The ic50 measured for 11 leukemic cells was 51 pM. The ic50 of BETd-260 in MOLM-13 cells was 2.2 nM. BETd-260 at 3-10 nM could induce RS4; 11 and MOLM-13 cell apoptosis. Moreover, BETd-260 inhibited the transcription and translation of anti-apoptotic genes Mcl-1, Bcl-2, c-Myc and XIAP and increased the transcription and translation of pro-apoptotic gene Bad in HCC cells[1]. |
In vivo | BETd-260, administered intravenously at a dosage of 5 mg/kg, effectively degrades the proteins BRD2, BRD3, and BRD4, maintaining this activity for over 24 hours. This process is accompanied by significant PARP and caspase-3 cleavage, along with a marked reduction in c-Myc protein levels in the RS4;11 xenograft mouse model[1]. When administered bi-weekly, three times a week for three weeks, BETd-260 induces rapid tumor regression, achieving a peak regression greater than 90% in RS4;11 xenograft tumor-bearing mice. Notably, this treatment regimen does not lead to weight loss or other toxicity symptoms in the mice. |
Synonyms | ZBC 260 |
Molecular Weight | 798.89 |
Formula | C43H46N10O6 |
CAS No. | 2093388-62-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (28.2 mM), Sonication is recommended.
H2O: 0.1 mg/mL, insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BETd-260 2093388-62-4 Chromatin/Epigenetic Epigenetic Reader Domain ZBC260 ZBC-260 ZBC 260 inhibitor inhibit